Insider Cluster (2 insiders) ·Filed Aug 4, 2026

RARE

Ultragenyx Pharmaceutical Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed1mo ago
Insider cluster: 2 insiders, $164K total
Actionable Insight • Neutral

This is a routine, immaterial insider sale cluster. The dollar amount is too small to warrant any trading action. Monitor for any upcoming material filings (earnings, pipeline updates) that could provide context, but these sales alone carry no signal.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d ⚠ clustered
RARE ▲ 0.00% at T+20d
NEUTRAL call ✗ call lost 0.00% · α vs SPY +1.24% · entry $25.81 → $25.81
Next anchor: T+60d in 26d
Latest observation: T+41 -49.27% FF3 residual α
Entry anchored
Aug 4, 03:15 PM ET
via exchange tick
T+1d
-3.41%
call -3.41% · α -3.21%
$24.93
settled 8w ago
T+5d
+4.46%
call +4.46% · α +4.56%
$26.96
settled 7w ago
T+20d
0.00%
call 0.00% · α +1.24%
$25.81
settled 4w ago
T+60d
—
call — · α —
—
in 26d

Price Chart

Loading chart...

Executive Summary

Two C-suite insiders at Ultragenyx (CFO and EVP/Chief Legal Officer) sold a combined $164K in open-market sales on August 3, 2026, at $24.92 per share. The total value is only ~0.007% of the $2.5B market cap, making this a trivial cluster by proportionality standards. The sales are not clustered with any recent material corporate event in the provided context, and the dollar amount is well below the threshold for signaling concern — this is routine portfolio diversification or tax planning, not informed selling.

Key Financial Metrics

Direction
selling
Total Value
$164.4K
Insiders
2

Key Facts

  • CFO Howard Horn sold 4,696 shares for $117K on 2026-08-03
  • EVP/CLO Karah Parschauer sold 1,900 shares for $47K on 2026-08-03
  • Total cluster value of $164K represents ~0.007% of $2.5B market cap
  • Both sales were open-market transactions at $24.92 per share
  • No recent earnings, guidance, or material corporate event in the provided context to connect to these sales

Financial Impact

Trivial — $164K total sales, ~0.007% of market cap

insider_ownership

Risk Factors

  • No material risk identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (25 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-RARE-1785871541587
12 reports for RARE
Performance horizon
83% Hit rate 5 of 6 directional calls best @ T+60▲ +48.73%Apr 2, 2026
Filters
Rows
Reports for RARE — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
8-K
BEARISH ★ 8/10
$14.85 $15.22▼ −2.49%▼ −3.68%$15.22 (−2.49%)
Sep 1, 2026
4w ago
Press Release
BULLISH ★ 7/10
$26.53 $15.03▼ −43.35%▼ −43.02%$15.22 (−42.63%)
Aug 11, 2026
7w ago
8-K
NEUTRAL ★ 4/10
$26.80 $14.31▼ −46.60%▼ −45.55%$15.22 (−43.21%)
Aug 4, 2026
8w ago
8-K
BULLISH ★ 6/10
$24.93 $26.53▲ +6.42%▲ +7.02%$15.22 (−38.95%)
Aug 4, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$25.81 $25.81· 0.00%▲ +1.24%$15.22 (−41.03%)
Jun 15, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.85 $32.03▲ +28.89%▲ +28.69%$15.22 (−38.75%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 4/10
$23.98 $34.61▲ +44.33%▲ +42.44%$15.22 (−36.53%)
May 5, 2026
21w ago
Press Release
BEARISH ★ 6/10
$25.93 $22.41▲ +13.57%▲ +16.36%$15.22 (+41.30%)
May 1, 2026
22w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.77 $22.85▼ −7.75%▼ −13.04%$15.22 (−38.55%)
Apr 2, 2026
26w ago
8-K
BULLISH ★ 8/10
$22.45 $24.69▲ +9.98%▲ +0.10%$15.22 (−32.20%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (64h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 4, 2026